Perioperative Anticoagulant Use for Surgery Evaluation (PAUSE) Study
Source: View publication →
The PAUSE study demonstrated that a standardized, simple perioperative management protocol for direct oral anticoagulants (DOACs)—involving fixed interruption intervals based on procedure bleeding risk and renal function—achieved low rates of major bleeding and arterial thromboembolism without the need for preoperative laboratory testing or heparin bridging.
Key Findings
Study Design
Study Limitations
Clinical Significance
The PAUSE protocol provides a validated, evidence-based standard of care that simplifies the perioperative management of DOACs. By demonstrating safety without the need for bridging anticoagulation or preoperative testing, this strategy reduces healthcare complexity, minimizes costs, and clarifies the management for clinicians and patients.
Historical Context
Prior to the PAUSE study, the perioperative management of DOACs was characterized by significant heterogeneity and uncertainty, often involving the suboptimal adoption of warfarin-style 'bridging' protocols. The PAUSE trial was initiated to establish a standardized, safer, and more efficient evidence-based approach that acknowledges the unique pharmacokinetic profiles of the DOAC agents.
Guided Discussion
High-yield insights from every perspective
The PAUSE study demonstrated that heparin bridging is generally unnecessary for patients on Direct Oral Anticoagulants (DOACs). Based on the pharmacokinetics of DOACs compared to warfarin, why is the 'bridge' with a shorter-acting agent like Lovenox considered essential for high-risk warfarin patients but detrimental for those on DOACs?
Key Response
Warfarin has a long half-life (~36-42 hours) and its effects take days to wash out and days to restart, creating a 'thromboembolic gap.' In contrast, DOACs have predictable, short half-lives (12-17 hours) and rapid onset. Adding a bridge to DOACs doesn't significantly narrow the sub-therapeutic window but does substantially increase the 'area under the curve' for bleeding risk, as evidenced by the low 0.4-0.6% arterial thromboembolism rate in PAUSE without bridging.
In the PAUSE protocol, the timing of DOAC interruption is dictated by the procedure's bleeding risk. How should a resident classify a laparoscopic cholecystectomy versus a spinal anesthetic procedure under this protocol, and what are the specific resumption rules for 'high-risk' procedures?
Key Response
Laparoscopic cholecystectomy is typically 'low-risk' (24-hour interruption), whereas spinal anesthesia is 'high-risk' due to the catastrophic nature of a spinal hematoma (48-hour interruption). For high-risk procedures, the PAUSE protocol mandates waiting 48-72 hours post-operatively before resuming the full dose of DOAC to ensure primary hemostasis is secure, whereas low-risk procedures can resume the next day.
The PAUSE study noted a specific exception for Dabigatran in patients with moderate renal impairment (CrCl 30-50 mL/min). Why did this cohort require a 4-day preoperative interruption for high-risk procedures compared to the standard 2-day interruption for Apixaban or Rivaroxaban?
Key Response
Dabigatran is uniquely dependent on renal clearance (~80%) compared to the Factor Xa inhibitors (Apixaban ~27%, Rivaroxaban ~33%). In patients with a CrCl <50 mL/min, the half-life of Dabigatran significantly prolongs, necessitating a longer washout period to ensure residual anticoagulant levels are below the <50 ng/mL safety threshold targeted by the study.
The PAUSE study achieved high safety outcomes without routine preoperative laboratory testing of DOAC levels. Does this evidence suggest we should abandon 'bridging' and 'pre-op levels' entirely in the elective setting, or are there specific 'grey-zone' populations where the PAUSE protocol may still be insufficient?
Key Response
While PAUSE provides a robust framework for the 'average' patient, attendings should recognize that it excluded patients with mechanical valves, severe renal failure (CrCl <25-30), and those with high-risk thrombophilia. In patients with extreme BMI or those undergoing neurosurgical procedures where even minimal residual anticoagulation is unacceptable, a pre-operative anti-Xa level or diluted thrombin time may still be a wise adjunct to the PAUSE timing.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
The PAUSE study utilized a prospective management cohort design with a fixed 'safety threshold' for major bleeding and stroke. Critique the statistical implications of using this design rather than a non-inferiority Randomized Controlled Trial (RCT) against 'standard of care' or warfarin-bridging controls.
Key Response
A management cohort allows for higher external validity and the study of a standardized clinical pathway, but it lacks a head-to-head comparison group. By using predefined safety benchmarks (e.g., <1% for stroke), the researchers assume historical data remains a stable comparator. A PhD-level critique would note that 'standard of care' was highly variable at the time, making an RCT difficult to power, but the cohort design cannot account for the 'Hawthorne effect' of protocol adherence within study sites.
As a reviewer, the 'residual drug level' substudy in PAUSE is a critical piece of the paper's impact. However, only a subset of patients had these levels measured. How does the discrepancy between the protocol's timing and the actual percentage of patients reaching the <50 ng/mL threshold affect the internal validity of the study's conclusions?
Key Response
Editors look for the 'biological plausibility' of a protocol. In PAUSE, over 90% of patients met the <50 ng/mL target for low-risk and 98-99% for high-risk procedures. A reviewer would flag if a large percentage of patients had high residual levels despite the protocol; the high 'success' rate of the pharmacokinetic target validates that the interruption intervals were appropriately calibrated to the drugs' half-lives.
The 2017 ACC Expert Consensus and 2018 EHRA guidelines had slight variations in DOAC interruption intervals. Does the PAUSE study provide sufficient Level 1 evidence to unify these guidelines into a single standardized interruption 'clock' for AFib patients, and how does it address the previous ambiguity regarding 'minimal' versus 'low' risk procedures?
Key Response
PAUSE provides some of the highest quality prospective data available (LOE B-R or A). It simplifies the previous 'sliding scales' into a binary risk model (Low vs. High). Current updates to the Chest (ACCP) and AHA/ACC guidelines have heavily integrated the PAUSE findings, moving away from 'minimal risk' distinctions toward a more pragmatic 'no-interruption' vs 'interruption' approach, effectively setting the PAUSE protocol as the new clinical standard for elective DOAC management.
Clinical Landscape
Noteworthy Related Trials
RE-LY Trial
Tested
Dabigatran (110mg or 150mg BID)
Population
Patients with atrial fibrillation at risk of stroke
Comparator
Warfarin
Endpoint
Stroke or systemic embolism
ARISTOTLE Trial
Tested
Apixaban 5mg BID
Population
Patients with atrial fibrillation
Comparator
Warfarin
Endpoint
Stroke or systemic embolism
ROCKET AF Trial
Tested
Rivaroxaban 20mg daily
Population
Patients with nonvalvular atrial fibrillation
Comparator
Warfarin
Endpoint
Stroke or systemic embolism
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis